

Prior authorization requests for Makena for Federal Employee Program members

In April 2023, the U.S. Food & Drug Administration withdrew its approval of Makena[®] (hydroxyprogesterone caproate), HCPCS codes J1726 and J1729, and generic Makena products. This change affects Blue Cross and Blue Shield Federal Employee Program[®] members.

For additional information, see:

- [April 6, 2023, FDA news release](#)*
- The [June 14, 2023, provider alert](#) in which we announced how we're handling prior authorization requests

[Subscribe](#) to Provider Alerts Weekly, a weekly email with a list of links to the previous week's provider alerts.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.